Literature DB >> 3702667

The double gammopathies. Clinical and immunological studies.

S Riddell, Z Traczyk, F Paraskevas, L G Israels.   

Abstract

A retrospective review of 1135 patients with paraproteinemias recorded 28 (2.5%) as having two M components. This group included 11 patients with myeloma, 6 with lymphoproliferative disease, 5 with a nonlymphoproliferative malignancy, and 6 with a double gammopathy of undetermined significance. In 13 cases in which the M components were measured over a period of time, three distinct patterns were observed, which may reflect the cellular and subcellular origin of the two proteins: 1) In 2 cases the minor component remained relatively stable while the dominant protein changed with time and treatment, suggesting the origin to be two cell lines--the minor arising from a quiescent clone of the monoclonal gammopathy of undetermined significance, and the major M component arising from a more rapidly proliferating plasma cell line; 2) a discordant pattern was seen in 4 patients, suggesting that the two M components arose from two separate plasma cell clones; 3) seven cases in which the proteins behaved in a concordant manner probably arose from a single plasma cell clone with incomplete class switching, producing two M components with different heavy chains.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3702667     DOI: 10.1097/00005792-198605000-00001

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  3 in total

1.  Occurrence of Double Monoclonal Bands on Protein Electrophoresis: An Unusual Finding.

Authors:  Vishrut K Srinivasan; Priyanka Bhagat; Frainey Bansal; Seema Chhabra
Journal:  Indian J Hematol Blood Transfus       Date:  2015-11-28       Impact factor: 0.900

Review 2.  Syndrome of plasma cell dyscrasia, polyneuropathy, and diabetes mellitus.

Authors:  M L Davies; D L Elson; D Hertz; J M McMillin
Journal:  West J Med       Date:  1990-03

3.  Active multiple myeloma suppresses and typically eliminates coexisting MGUS.

Authors:  John P Campbell; Jennifer L J Heaney; Sankalp Pandya; Zaheer Afzal; Martin Kaiser; Roger Owen; J Anthony Child; Walter Gregory; Gareth J Morgan; Graham H Jackson; Chris M Bunce; Mark T Drayson
Journal:  Br J Cancer       Date:  2017-07-20       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.